Detail publikace

Histone deacetylase inhibitors in cancer therapy. A review

HRABĚTA, J. STIBOROVÁ, M. ADAM, V. KIZEK, R. ECKSCHLAGER, T.

Originální název

Histone deacetylase inhibitors in cancer therapy. A review

Typ

článek v časopise ve Web of Science, Jimp

Jazyk

angličtina

Originální abstrakt

Different HDAC inhibitors induce cancer cell death by different mechanisms that include changes in gene expression and alteration of both histone and non-histone proteins. Enhanced histone acetylation in tumors results in modification of expression of genes involved in cell signaling. Inhibition of HDACs causes changed expression in 2-10 % of genes involved in important biological processes. The results of experiments and clinical studies demonstrate that combination of HDAC inhibitors with some anticancer drugs have synergistic or additive effects.

Klíčová slova

chromatin remodeling, histone acetylation, histone deacetylases, histone deacetylase inhibitors, combined treatment modalities, mechanisms of combined treatment

Autoři

HRABĚTA, J.; STIBOROVÁ, M.; ADAM, V.; KIZEK, R.; ECKSCHLAGER, T.

Rok RIV

2014

Vydáno

1. 6. 2014

ISSN

1213-8118

Periodikum

Biomedical Papers

Ročník

158

Číslo

2

Stát

Česká republika

Strany od

161

Strany do

169

Strany počet

9

BibTex

@article{BUT112436,
  author="Jan {Hraběta} and Marie {Stiborová} and Vojtěch {Adam} and René {Kizek} and Tomáš {Eckschlager}",
  title="Histone deacetylase inhibitors in cancer therapy. A review",
  journal="Biomedical Papers",
  year="2014",
  volume="158",
  number="2",
  pages="161--169",
  doi="10.5507/bp.2013.085",
  issn="1213-8118"
}